Surrogate endpoint trang 1 tải miễn phí từ tailieunhanh

"Surrogate endpoint" trang 1 - tải miễn phí từ tailieunhanh

Identification on surrogating overall survival with progression-free survival of first-line immunochemotherapy in advanced esophageal squamous cell carcinoma—an exploration of surrogate endpoint

Identification on surrogating overall survival with progression-free survival of first-line immunochemotherapy in advanced esophageal squamous cell carcinoma—an exploration of surrogate endpoint

13 4 1

Disease-free survival as a surrogate endpoint for overall survival in adjuvant trials of pancreatic cancer: A meta-analysis of 20 randomized controlled trials

Disease-free survival as a surrogate endpoint for overall survival in adjuvant trials of pancreatic cancer: A meta-analysis of 20 randomized controlled trials

10 69 0

Identification of surrogate endpoints in patients with locoregionally advanced nasopharyngeal carcinoma receiving neoadjuvant chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone

Identification of surrogate endpoints in patients with locoregionally advanced nasopharyngeal carcinoma receiving neoadjuvant chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone

8 41 1

Progression-free survival at 2 years is a reliable surrogate marker for the 5-year survival rate in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy

Progression-free survival at 2 years is a reliable surrogate marker for the 5-year survival rate in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy

5 41 1

Validating ORR and PFS as surrogate endpoints in phase II and III clinical trials for NSCLC patients: Difference exists in the strength of surrogacy in various trial settings

Validating ORR and PFS as surrogate endpoints in phase II and III clinical trials for NSCLC patients: Difference exists in the strength of surrogacy in various trial settings

13 1 1

Food and Drug Administration approvals in phase 3 Cancer clinical trials

Food and Drug Administration approvals in phase 3 Cancer clinical trials

6 69 1